Grail Signs on Quest Diagnostics to Provide Phlebotomy for Cancer Detection Test
GRAIL has entered an agreement with Quest Diagnostics to provide phlebotomy services in support of its multi-cancer early detection blood test. The test, called Galleri, is expected to go to market in the second quarter after its PATHFINDER multi-site interventional study. Under the agreement, Quest’s phlebotomy network, which is composed of approximately 2,200 patient service centers and 5,000 mobile phlebotomists, will help GRAIL with its specimen collection when Galleri is launched. “Today, the majority of cancers go undetected until too late when outcomes are often deadly, and we...